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A B S T R A C T
Amorphous materials are inherently unstable and tend to crystallize upon storage. In this study, we
investigated the extent to which the physical stability and inherent crystallization tendency of drugs are
related to their glass-forming ability (GFA), the glass transition temperature (Tg) and thermodynamic
factors. Differential scanning calorimetry was used to produce the amorphous state of 52 drugs
[18 compounds crystallized upon heating (Class II) and 34 remained in the amorphous state (Class III)]
and to perform in situ storage for the amorphous material for 12 h at temperatures 20 C above or below
the Tg. A computational model based on the support vector machine (SVM) algorithm was developed to
predict the structure-property relationships. All drugs maintained their Class when stored at 20 C below
the Tg. Fourteen of the Class II compounds crystallized when stored above the Tg whereas all except one of
the Class III compounds remained amorphous. These results were only related to the glass-forming
ability and no relationship to e.g. thermodynamic factors was found. The experimental data were used for
computational modeling and a classiﬁcation model was developed that correctly predicted the physical
stability above the Tg. The use of a large dataset revealed that molecular features related to aromaticity
and p–p interactions reduce the inherent physical stability of amorphous drugs.
ã 2015 Elsevier B.V.. Published by Elsevier B.V.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Drugs that are in an amorphous state have signiﬁcantly
different properties from those of their crystalline counterparts.
When poorly soluble drugs are in an amorphous state, they have a
higher dissolution rate and are more soluble (Hancock et al., 2002;
Hancock and Parks, 2000; Marsac et al., 2006a). There has been
increasing interest in incorporating poorly soluble drugs in
medicinal products in their amorphous form, in order to improve
their absorption, and hence their bioavailability. However,
amorphous materials are not stable and their tendency to
crystallize is a challenge when formulations of the amorphous
form of the drug are being developed (Hancock et al., 1995;
Yoshioka et al.,1994; Yu, 2001). Research efforts have been directed
towards improved understanding of the driving force for
crystallization in these materials and the conditions that might
prolong their physical stability (Andronis and Zograﬁ, 1998;
Hancock et al., 1995, 1998; Kauzmann, 1948; Yoshioka et al.,* Corresponding author. Fax: +46 18 471 4223.
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kinetically stable if it is stored at a temperature well below the
glass transition temperature (Tg) (Andronis and Zograﬁ, 1998;
Hancock et al., 1995; Kauzmann, 1948). The Tg is an intrinsic
property of amorphous materials and is therefore often used to
indicate their physical stability (Angell, 1988). The physical
properties of the materials above and below the Tg are different
and reﬂect the physical stability of the material (Andronis and
Zograﬁ, 1998; Graeser et al., 2009; Hancock et al., 1995; Yoshioka
et al., 1994). The material is considered to exist in a glassy (solid)
state below the Tg and as a supercooled liquid above the Tg.
Currently, the mechanistic understanding of the driving force for
crystallization above and below the Tg is sparse and studies of the
chemical modiﬁcations or formulation strategies that might result
in improved performance of amorphous solid dosage forms are
warranted.
The stability of amorphous materials upon storage above and
below the Tg has been investigated in several studies, but in each of
these only a limited number of compounds has been included
(Andronis and Zograﬁ, 1998; Graeser et al., 2009; Hancock et al.,
1995; Yoshioka et al.,1994). These studies linked the crystallization
process to molecular mobility, which increases at higherder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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have a higher tendency to crystallize above than below the Tg.
Other studies have found that molecular mobility is not predictive
enough to be used as the only determinant for stability in the
amorphous state and that other factors such as the conﬁgurational
entropy(Zhou et al., 2002) and enthalpy (Marsac et al., 2006b) have
signiﬁcant impact on the stability (Graeser et al., 2009; Hancock
et al., 1998).
In the area of material science, the stability of the amorphous
state has been deﬁned as the resistance of glasses to devitriﬁcation
upon reheating (especially near or somewhat above the Tg)
(Weinberg,1994). The relationship between glass stability (GS) and
glass-forming ability (GFA) has been explored, but only modestTable 1
Compounds used in the study with their molecular weight (MW), melting temperatur
stability test above Tg (Tabove = Tg + 20), change in free energy (DG) between the supercool
and yes = amorphous). Pi_AQc = sum of absolute values of Hückel pi atomic charges on C a
set; TS = test set.
Compound Class MW (g/mole) Tm (K) DH kJ/mole Tg (K) Tabov
Acetaminophen II 151.2 443 29 299 319 
Celecoxib II 318.4 436 32 331 351 
Danazol II 337.5 500 36 352 372 
Estradiol II 22.4 451 2 358 378 
Nifedipine II 346.3 446 39 320 340 
Orlistat II 495.8 316 56 228 248 
Pimozide II 461.6 492 50 335 355 
Tamoxifen II 371.5 371 56 263 283 
Tenofovir II 28.2 552 3 416 436 
Testosterone II 288.4 426 26 315 335 
Tinidazole II 247.3 289 36 266 286 
Tolazamide II 311.4 445 41 297 317 
Aripiprazole II 448.4 517 48 363 383 
Bicalutamide II 430.4 465 51 323 343 
Cinnarizine II 368.5 394 43 280 300 
Clemastine II 343.9 451 48 308 328 
Fluorescamine II 278.3 426 28 299 319 
Flurbiprofen II 244.3 388 28 270 290 
Acemetacin III 415.8 421 48 310 330 
Budesonide III 430.5 530 39 368 388 
Captopril III 217.3 380 29 277 297 
Carvedilol III 406.5 390 53 315 335 
Chloramphenicol III 323.1 425 4 304 324 
Chlorhexidine III 505.5 408 43 336 356 
Clotrimazole III 344.9 418 35 303 323 
Emtricitabine III 247.2 426 27 344 364 
Ezetimibe III 409.4 437 40 338 358 
Felodipine III 384.3 420 34 318 338 
Hydrocortisone III 362.5 497 45 359 379 
Ibuprofenb III 206.3 350 27 228 248 
Indomethacin III 356.7 434 42 318 338 
Itraconazole III 705.7 441 65 331 351 
Ketoprofen III 254.3 368 31 270 290 
Linaprazan III 366.5 519 55 373 393 
Metolazone III 365.8 539 36 382 402 
Nizatidine III 331.5 406 45 286 306 
Physostigmine III 275.4 377 32 293 313 
Simvastatin III 418.8 412 29 309 329 
Spironolactone III 416.6 486 24 364 384 
Sulindac III 356.4 460 32 348 368 
Zolmitriptan III 287.4 410 34 322 342 
Bucindolol III 363.5 459 38 356 376 
Fenoﬁbrateb III 360.8 354 35 256 276 
Glafenine III 372.8 437 43 337 357 
Glibenclamide III 494 445 51 333 353 
Hydrochlorothiazide III 297.7 536 34 391 411 
Hydroﬂumethiazide III 297.9 542 39 373 393 
Isradipine III 371.4 432 34 316 336 
Ketoconazole III 531.4 423 54 318 338 
Nandrolone III 274.4 397 21 310 330 
Nimesulideb III 308.3 423 36 296 316 
Warfarin III 308.3 435 45 345 365 
a No = not amorphous after the stability study; yes = amorphous after the stability stu
b Behaved like a Class II drug after the stability study.relationships have been reported (Baird et al., 2010; Mahlin and
Bergström, 2013; Mahlin et al., 2011; Nascimento et al., 2005).
However, a classiﬁcation system based on the GFA of drug
compounds has recently been presented and this system has
been related to the GS of the compounds (Baird et al., 2010; Mahlin
and Bergström, 2013; Mahlin et al., 2011). In these studies, the
crystallization tendency scheme designed by Taylor and coworkers
was used (Baird et al., 2010). They divided compounds into three
classes, depending on how easily the compounds crystallized
during a heat-cool-heat cycle. Class I compounds are deﬁned as
those that crystallize upon cooling the melt, whereas Class II and
Class III compounds form an amorphous material upon cooling the
melt. Class II and III compounds are differentiated in that Class IIe (Tm), heat of fusion (DH), glass transition temperature (Tg), temperature for the
ed liquid and the crystalline state at T, and result of the stability test (no = crystalline
toms; F_AromB = number of aromatic bonds as a fraction of total bonds; TR = training
e (K) Tg/Tabove DG (kJ/mol) Stable above Tga Pi_AQc F_AromB TR/TS
0.94 5.9 No 0.48 0.55 TR
0.94 5.1 No 0.45 0.61 TR
0.95 6.8 No 0.15 0.17 TR
0.95 0.3 No 0.22 0.26 TR
0.94 7.0 No 1.00 0.23 TR
0.92 9.4 No 0.72 0 TR
0.94 10.1 No 0.53 0.58 TR
0.93 10.2 Yes 0.24 0.60 TR
0.95 1.2 No 0.29 0.50 TR
0.94 4.4 No 0.40 0 TR
0.93 0.4 No 0.20 0.31 TR
0.94 8.3 Yes 0.40 0.27 TR
0.95 9.2 No 0.94 0.36 TS
0.94 9.9 No 0.82 0.40 TS
0.93 7.7 Yes 0.03 0.58 TS
0.94 9.6 No 0.09 0.46 TS
0.94 5.7 Yes 0.83 0.50 TS
0.93 5.4 No 0.38 0.63 TS
0.94 8.1 Yes 1.34 0.52 TR
0.95 7.6 Yes 0.73 0 TR
0.93 4.9 Yes 0.46 0 TR
0.94 6.4 Yes 0.83 0.64 TR
0.94 0.7 Yes 0.39 0.30 TR
0.94 4.7 Yes 0.86 0.34 TR
0.94 6.1 Yes 0.29 0.82 TR
0.95 3.4 No 0.41 0.35 TR
0.94 6.0 Yes 0.74 0.55 TR
0.94 5.3 Yes 0.93 0.23 TR
0.95 8.1 Yes 0.69 0 TR
0.92 5.5 Yes 0.30 0.40 TR
0.94 7.2 Yes 1.10 0.59 TR
0.94 10.6 Yes 1.02 0.51 TR
0.93 5.2 Yes 0.72 0.60 TR
0.95 10.1 Yes 0.73 0.55 TR
0.95 6.8 Yes 0.87 0.46 TR
0.93 8.4 Yes 0.50 0.24 TR
0.94 4.5 Yes 0.47 0.27 TR
0.94 4.6 Yes 0.51 0 TR
0.95 4.0 Yes 0.90 0 TR
0.95 5.2 Yes 0.74 0.44 TR
0.94 4.7 Yes 0.56 0.43 TR
0.95 5.6 Yes 0.79 0.55 TS
0.93 6.1 Yes 0.91 0.46 TS
0.94 6.4 Yes 0.90 0.61 TS
0.94 8.3 Yes 0.81 0.34 TS
0.95 6.1 Yes 0.61 0.33 TS
0.95 7.9 Yes 0.48 0.29 TS
0.94 5.8 Yes 0.86 0.34 TS
0.94 8.7 Yes 0.90 0.43 TS
0.94 2.9 Yes 0.41 0 TS
0.94 6.7 Yes 0.43 0.55 TS
0.95 6.0 Yes 1.03 0.68 TS
dy.
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whereas Class III compounds remain amorphous (Baird et al., 2010;
Mahlin and Bergström, 2013). The physical stability of the
amorphous form of a drug has been related to thermodynamic
factors, and factors such as viscosity and the entropy difference
between the melt and the undercooled liquid have been suggested
to be driving forces for crystallization (Bhugra and Pikal, 2008;
Kawakami et al., 2014; Trasi et al., 2014). However, the
thermodynamic properties are difﬁcult to assess below the Tg
and have only been related to physical stability above the Tg for a
limited number of compounds (Graeser et al., 2009).
This work investigated the relationships between the physical
stability above and below the Tg under dry conditions to gain a
better understanding of the deviations existing in the relation
between storage stability and Tg. A large number of drug
compounds were studied to provide a mechanistic understanding
of the driving forces behind crystallization. The relationship
between the Tg and the physical stability, and the change in free
energy (DGv) between the melt and the crystalline state and the
physical stability after storage was investigated. Further, compu-
tational models that predict the physical stability of compounds
from their molecular structure were developed to better under-
stand the molecular properties that are important for glass
stability.
2. Methods
2.1. Materials
All chemicals were of high purity (98.0–99.9%) and purchased
from Sigma–Aldrich (Stockholm, Sweden) except for danazol
(Coral drugs IVT, India), itraconazole (Lee Pharma Ltd., India)
ezetimibe and ketoconazole (TCR, Toronto, Canada) and bicaluta-
mide, felodipine and linaprazan which were received as a kind gift
from AstraZeneca (Mölndal, Sweden), The compounds were
selected to provide a wide range of Tgs (225–425 K; Table 1) and
all were previously identiﬁed as compounds with GFA (Alhalaweh
et al., 2014).
2.2. Production of the amorphous state
The amorphization of each compound was performed by in situ
quenching in a differential scanning calorimetry (DSC) Q2000 (TA)
instrument calibrated for temperature and enthalpy using indium.
The instrument was equipped with a refrigerated cooling system.
The melting point and heat of fusion were determined for each
compound using an amount of 1–3 mg in non-hermetic aluminium
pans. The compounds were scanned at a heating rate of 10 C/min
under a continuously purged dry nitrogen atmosphere (50 mL/
min).
Glass formation was investigated by weighing 1–3 mg of the
compound into a non-hermetic pan and heating to about 2 C
above the peak melting temperature. The system was kept
isothermal for 2 min to obtain complete melting and was
thereafter cooled to 70 C at a ramp rate of 20 C/min. The
formation of an amorphous state was then investigated by
performing a second heat cycle using a heating rate of 20 C/
min immediately after cooling. The production of an amorphous
state was indicated by detection of the Tg upon heating.
2.3. In situ storage in the DSC instrument
After formation of the amorphous materials described in the
previous section, an in situ storage study was performed in the DSC
instrument. A time frame of 12 h was used and the study wasperformed twice: 20 C above and 20 C below the Tg. The following
experimental protocol was used. The sample was:
1. heated to about 2 C above the peak melting temperature, and
was thereafter kept isothermal for 2 min to ensure complete
melting, followed by cooling to 70 C at a ramp rate of 20 C/
min to produce the amorphous material;
2. heated to 20 C above the Tg at 20 C/min and then cooled to
40 C below the Tg at the same heating rate to remove any
thermal history;
3. heated to the storage temperature (20 C above or below the Tg)
and held at this temperature for 12 h;
4. cooled to 40 C below the Tg at 20 C/min;
5. heated to 20 C above melting temperature at a ramp rate of
20 C/min.
The DGv between the liquid and crystalline phases was
calculated by the Hoffman equation (Hoffman, 1958):
DGv ¼ DHf Tm  Tð ÞT
T2m
where DHf is the heat of fusion of the crystalline material, Tm is the
melting temperature, and T is the temperature of storage.
3.1. Model development
The computational model was developed using 52 compounds
and their corresponding molecular descriptors. The total number
of descriptors was 280 which were calculated with the software
ADMET Predictor (SimulationsPlus, CA) using molecules repre-
sented as structure-data ﬁles (sdf). The dataset was divided into
training (35 compounds) and test (17 compounds) sets based on
the Tg values and the Class (II or III) of the compounds. A support
vector machine (SVM) algorithm was used to build a prediction
model, making use of the forward selection procedure. Support
vector machine is a supervised learning method which is
considered as one of the most successful classiﬁcation methods
(Suykens and Vandewalle, 1999). The SVM algorithm makes a
decision boundary that maximizes the margin between two
classes. SVMs also take advantage of nonlinear kernels such as
polynomial and Gaussian functions to efﬁciently perform a non-
linear classiﬁcation by mapping the data into a high dimensional
space where it can be linearly separated. The model development
procedures started by applying a two-sample t-test to the training
set for all molecular descriptors (n = 280). The variable that
achieved the lowest p-value was selected for further investigation.
This variable was used with the remaining 279 descriptors, one at a
time, as inputs into the SVM model. A ﬁve-fold cross-validation
method was applied to the training set to assess the performance
of the SVM model for each added descriptor. This procedure was
repeated until no improvement in the performance of the model
was noticed.
The performance of the SVM model changes as the values of the
SVM parameters change. A leave-one-out cross-validation
(LOOCV) was used to tune the parameters. The LOOCV involved
dividing the data into two groups: the training and testing sets.
Only one observation is used for testing, and the rest of data are
used for training. The process is then repeated for all observations
(i.e. all compounds) so that every observation is left out in turn
from the model development and tested. In this work, the LOOCV
was used to assess the performance of the SVM model when its
sigma parameter was changed. The sigma value which achieved
the lowest classiﬁcation error was assigned to the SVM model.
Table 2
Heat capacity change at Tg (DCp) (J g C1) for Class II compounds analysed at time 0
and after 12 and 24 h0 storage.
Time (h) Cinnarizine Fluorescamine Tamoxifen Tolazamide
0 0.57 0.48 0.49 0.55
12 0.54 0.42 0.46 0.22
24 0.33 0.27 – 0.22
Fig. 2. Stability results for Class III compounds; n = 34; stored above the Tg.
Fig. 3. Stability results for Class III compounds that remained amorphous when
stored above the Tg; n = 33.
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This study was carried out to gain a better molecular
understanding of the stability of amorphous compounds and,
hence, only compounds that had previously been identiﬁed as
good glass-formers were investigated (Alhalaweh et al., 2014;
Alzghoul et al., 2014). However, compounds from both Class II
(where recrystallization occurs upon heating) and Class III (where
no recrystallization occurs upon heating) were included. The
stability of these compounds was studied under standardized
conditions with regard to the Tg. A temperature of 20 C above and
below the Tg was selected, based on the reasoning that all
compounds should have the same Tg/T and therefore should have
similar prerequisites for crystallization (Table 1). The value of Tg/T
correlates well with the initiation time for crystallization, so this
effect was normalized (Kawakami et al., 2014).
3.2. Physical stability
There was no change in the solid state when the compounds
were stored below the Tg. Therefore, the physical stability of the
compound below the Tg on the timescale used (12 h) is highly
related to the GFA (Alhalaweh et al., 2014; Baird et al., 2010). The
general trend for Class II compounds when stored above the Tg was
that they rapidly crystallized (Fig. 1). Among the 18 Class II
compounds, only four remained amorphous after the challenge of
elevated temperature. These were tolazamide, cinnarizine, ﬂuo-
rescamine and tamoxifen. All the other Class II compounds
crystallized upon storage, as conﬁrmed by the DSC analysis, as
there was no sign of a Tg in the second heating and the enthalpy on
melting corresponded to that of the crystalline drug. However, the
difference in heat capacity change at the Tg (DCp) for the four stable
compounds was lower after storage than at time zero (Table 2).
This suggested that the compounds might crystallize upon long
term storage and we therefore extended the stability study to 24 h
for these substances. After the additional 12 h at the elevated
temperature, tamoxifen crystallized and the remaining com-
pounds remained amorphous with further reduced DCp values
(Table 2).
The results for the stability of the Class III compounds are
presented in Fig. 2. Thirty-three of the 34 compounds (97%)
remained amorphous after storage, with emtricitabine the onlyFig. 1. Stability results for Class II compounds; n = 18; stored above the Tg.exception. Although a Tg was detected for nimesulide, fenoﬁbrate
and ibuprofen, they behaved like Class II compounds, i.e
crystallized upon heating, after storage (Fig. 3). Further, the DCp
at the Tg for these compounds after storage was lower than at time
zero (Table 3).
This study indicates that the physical state of the material has a
clear effect on the crystallization tendency. This was more
pronounced for Class II compounds, which all crystallized when
in a supercooled liquid state. Therefore, the storage of amorphous
Class II drugs with low Tg values is critical, as the drug will have a
high propensity for crystallization.
Fig. 4 shows the relationship between the Tg and the physical
stability at temperatures above the Tg. The compounds were
investigated under similar conditions and, thus, it is expected that
their behaviour will reﬂect their molecular properties. As can be
seen over the range of Tgs, which in this study covers 200 K, some
compounds with similar Tgs behaved in opposite ways. The Tg was
thus found not to be a factor of importance for the amorphous
behaviour and crystallization tendency near the Tg of a compound.
However, it was found that it was mainly compounds from Class III
that remained amorphous after 12 h at the elevated temperature,
while Class II compounds crystallized. Above the Tg, the material is
less viscous (more liquid-like) and the molecular mobility is
higher, leading to faster crystallization (Kothari et al., 2014;
Yoshioka et al., 1994). However, it has been shown that theTable 3
Heat capacity change at Tg (DCp) (J g C1) at time 0 and after 12 h0 storage for Class
III compounds that behaved like Class II compounds after storage.
Time (h) Ibuprofen Fenoﬁbrate Nimesulide
0 0.43 0.48 0.50
12 0.43 0.18 0.41
Fig. 4. Relationship between the Tg and the solid-state type (amorphous/
crystalline) after the stability study for Class II (blue star) and Class III (black
circle) compounds.
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crystallization tendency during storage (Mahlin and Bergström,
2013; Trasi et al., 2014). Molecular descriptors reﬂecting symmetry,
electrotopology, polarizability and molecular size have been used
to predict stability, and for instance larger drug molecules typically
are less prone to crystallize (Mahlin and Bergström, 2013;
Alhalaweh et al., 2014).
The relationship between the tendency to crystallize and the
DGv was investigated to discover the extent to which this
thermodynamic property is reﬂected in the classiﬁcation system
(Fig. 5 and Table 1). No clear trend was found, which is in
agreement with other ﬁndings in the literature (Trasi et al., 2014).
However, it has been predicted earlier that the driving force for
nucleation increases with increased DGv;;; as shown by increased
heat of fusion (Bhugra and Pikal, 2008). This relationship did not
hold for our data set (Fig. 5).
Our results show that Class II compounds crystallized from
supercooled liquid when they were kept for a longer time, while
Class III compounds were not affected. This clearly distinguishes
the behaviour of Class II drugs from that of Class III drugs. The class
II compounds did not crystallize from the glassy state, which
demonstrate the impact of the physical state on crystallization as
well as the inability to relate the crystallization from a supercooled
liquid to that from the glassy state.Fig. 5. Relationship between the free energy change and the stability result
(amorphous/crystalline) after storage above the Tg for Class II (blue star) and Class III
(black circle) compounds.3.3. Model prediction of physical stability
Computational prediction of drug properties from the molecu-
lar properties at an early stage in drug development is of great
interest (Alhalaweh et al., 2013, 2014; Alzghoul et al., 2014). Since
none of the compounds crystallized below Tg, computational
modeling was only done on stability data from studies above the Tg.
It was found that the descriptor reﬂecting the Hückel pi atomic
charges for carbon atoms had the lowest p-value (0.02) when the
two-sample t-test was performed. Analysis of this descriptor
showed that compounds with Hückel pi atomic charge values for
carbon atoms greater than 0.5 remain amorphous (17 out of 20)
upon storage above the Tg. However, it was not possible to
differentiate compounds when this descriptor was less than 0.5.
Therefore, other descriptors (i.e. all 280 descriptors except Hückel
pi atomic charges for carbon atoms) were gradually added, one at a
time, to see if the performance improved. The best performance
was seen when the value representing the fraction of aromatic
bonds was added to the Hückel pi atomic charges for carbon atoms
descriptor. The addition of still more descriptors did not improve
the result. Thus, the ﬁnal SVM model was trained using the whole
training data set, represented by these two descriptors, and using a
radial basis function (RBF) kernel with sigma = 0.8. The results
showed that the proposed SVM-based prediction model was able
to correctly classify the stability of the compounds above the Tg for
83% of the training set, and 82% of the test set, as shown in Fig. 6.
The good classiﬁcation accuracy shows that the SVM decision
boundary (i.e the red line in Fig. 6) well-separated compounds that
were amorphous after the stability study (green circle in Fig. 6) and
crystalline after the stability study (blue triangular in Fig. 6). The
Hückel and aromaticity parameters affect the molecular confor-
mation, (Alonso et al., 2014; Pulkkinen et al., 2000) and the
molecular conformation affects the crystallization of the molecule
(Back et al., 2012; Bar and Bernstein, 1987; Bernstein and Hagler,
1978). Compounds with more aromatic bonds seem to crystallize
faster at storage conditions above the Tg. Some compounds with
high Hückel values are lacking aromatic structures and have a
lower crystallization propensity. However, our model identiﬁed
two important parameters that can classify the tendencies of
compounds to crystallize from the supercooled liquid. Other
factors that we have identiﬁed earlier, such as the molecularFig. 6. Prediction of glass stability using the support vector machine algorithm for
all the study compounds that were amorphous after the stability study (green
circle) and crystalline after the stability study (blue triangular). The crosses indicate
the test set. Red line indicates the boundary generated by the SVM model.
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classiﬁcation of the compounds into Class II or Class III.
These results indicate that the chemical structure of the
compound signiﬁcantly impacts on its crystallization tendencies
and can be used, for example, to determine the stability of two
compounds with similar Tgs without the need for experimental
determination of, for example, the class.
4. Conclusion
This study investigated the crystallization tendency and
physical stability upon storage of a series of drugs as a function
of temperature. All the compounds were stored at 20 K below and
above their Tgs to explore their inherent stability and it was
revealed that the GFA can be used to predict the physical stability. It
was found that Class III compounds remained amorphous under
the studied dry conditions. In contrast, the majority of Class II
compounds crystallized when stored at 20 K above the Tg but
remained amorphous when stored at 20 K below the Tg. The Tg was
poorly correlated to the physical stability under the studied
conditions, further strengthening previous indications that mo-
lecular properties has a considerable impact on both the GFA and
the GS. For Class II compounds, the physical state inﬂuenced the
crystallization tendency; crystallization was faster from an under-
cooled liquid state than from a glassy state. The developed
computational model predicted the stability of the compounds
above Tg well, using two chemical descriptors: Hückel pi atomic
charges for carbon atoms and aromaticity. To conclude, this study
supports previous ﬁndings that the molecular structure of a
compound holds key information about the GFA and stability of the
amorphous state and can be used to better understand, and also to
predict, these complex properties.
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